Dr Paul Lorigan is a Reader in Medical oncology at the University of Manchester and Honorary Consultant Medical Oncologist at the Christie NHS Foundation Trust.

Dr Lorigan leads a research based clinical team, specialising in developing new treatments for malignant melanoma. 

Dr Lorigan is Chair Elect of Melanoma Focus, the UK national charity dedicated to research, treatment, education and information for clinical teams treating melanoma patients, for patients and their families. He chaired the UK NCRI Melanoma Clinical Studies Group from 2006 to 2012, and is a member of the EORTC Melanoma Group. 

He is principal investigator on a number of international clinical trials. The Manchester group, a collective of researchers and academics, are international leaders in research and treatment of melanoma. Manchester is the only centre in the UK able to deliver Adoptive Cell Therapy for melanoma, and only one of three in Europe. Dr Lorigan leads the clinical team that works closely with these groups, developing a model of personalised medicine in melanoma. This also allows a link between research in targeted therapy and immunotherapy, which greatly strengthens the centre's research output and competitive ability with the other five to six main centres leading internationally in this area. 

Paul Lorigan has been involved in a number of other projects. He was expert advisor to NICE in the Single Technology Appraisals (STA) of both ipilimumab and vemurafenib, is an advisor to Factor 50, and is a member of the Melanoma Forum. He also acts in the advisory capacity to many national and international groups.  He is principal investigator on a number of international studies in this area and has been a co-author on many of the definitive studies in the last 10 years. Dr Lorigan has published over 100 peer reviewed papers.